VAERS Explorer
Back to explore

Report #2837768

Received Apr 24, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
IN
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
MMRMEASLES + MUMPS + RUBELLA (PRIORIX)GLAXOSMITHKLINE BIOLOGICALSUNK—IM

Symptoms (1)

Incorrect route of product administration

Symptom narrative

unfortunately some of them have been administered intramuscularly; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in specified number of patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: unfortunately some of them have been administered intramuscularly). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 21-APR-2025 The Clinical Pharmacy Manager called to inform the following about Priorix vaccine but unfortunately some of them had been administered intramuscularly, which led to subcutaneous injection formulation administered by other route. The reporter clarified that two patients had received Priorix via intramuscular administration. The gender of the patients was unknown, as well as other details such as lot number, expiration date or date of administration. The reported consented to follow up.